Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Thus, there is an urgent need for safe and effective novel therapies. PDAC’s excessive reliance on glucose metabolism for its metabolic needs provides a target for metabolic therapy. Preclinical PDAC models have demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Lauren K., Lim, Kian-Huat, Volkman, Jonas, Abdiannia, Mina, Johnston, Hannah, Nigogosyan, Zack, Siegel, Marilyn J., McGill, Janet B., McKee, Alexis M., Salam, Maamoun, Zhang, Rong M., Ma, Da, Popuri, Karteek, Chow, Vincent Tze Yang, Beg, Mirza Faisal, Hawkins, William G., Peterson, Linda R., Ippolito, Joseph E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193807/
https://www.ncbi.nlm.nih.gov/pubmed/37202813
http://dx.doi.org/10.1186/s40170-023-00306-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193807/
https://www.ncbi.nlm.nih.gov/pubmed/37202813
http://dx.doi.org/10.1186/s40170-023-00306-2

Ejemplares similares